Febuxostat provides renoprotection in patients with hyperuricemia or gout: a systematic review and meta-analysis of randomized controlled trials

References

• White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1–11. doi: 10.1056/NEJMoa1710895.
   PubMed Web of Science ®Google Scholar
• Deng H, Zhang BL, Tong JD, et al. Febuxostat use and risks of cardiovascular disease events, cardiac death, and all-cause mortality: meta-analysis of randomized controlled trials. J Rheumatol. 2021;48(7):1082–1089. doi: 10.3899/jrheum.200307.
   PubMed Web of Science ®Google Scholar
• Kanji T, Gandhi M, Clase CM, et al. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrol. 2015;16(1):58. doi: 10.1186/s12882-015-0047-z.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhai T, Ma R, et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail. 2018;40(1):289–297. doi: 10.1080/0886022X.2018.1456463.
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang Z, Zhou J, et al. Effect of urate-lowering therapy on cardiovascular and kidney outcomes: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2020;15(11):1576–1586. doi: 10.2215/CJN.05190420.
   PubMed Web of Science ®Google Scholar
• Jeong HJ, Park WY, Kim SH, et al. Urate-lowering efficacy and renal safety of febuxostat in patients with hyperuricemia and stage 4-5 chronic kidney disease not yet on dialysis: a meta-analysis of observational studies. Semin Arthritis Rheum. 2022;56:152073. doi: 10.1016/j.semarthrit.2022.152073.
   PubMed Web of Science ®Google Scholar
• Badve SV, Pascoe EM, Tiku A, et al. Effects of allopurinol on the progression of chronic kidney disease. N Engl J Med. 2020;382(26):2504–2513. doi: 10.1056/NEJMoa1915833.
   PubMed Web of Science ®Google Scholar
• Doria A, Galecki AT, Spino C, et al. Serum urate lowering with allopurinol and kidney function in type 1 diabetes. N Engl J Med. 2020;382(26):2493–2503. doi: 10.1056/NEJMoa1916624.
   PubMed Web of Science ®Google Scholar
• Luo Q, Cai Y, Zhao Q, et al. Effects of allopurinol on renal function in patients with diabetes: a systematic review and meta-analysis. Ren Fail. 2022;44(1):806–814. doi: 10.1080/0886022X.2022.2068443.
   PubMed Web of Science ®Google Scholar
• McHugh ML. Interrater reliability: the kappa statistic. Biochem Med. 2012;22(3):276–282. doi: 10.11613/BM.2012.031.
   PubMed Web of Science ®Google Scholar
• IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14(1):25. doi: 10.1186/1471-2288-14-25.
   PubMedGoogle Scholar
• Goldfarb DS, MacDonald PA, Gunawardhana L, et al. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. Clin J Am Soc Nephrol. 2013;8(11):1960–1967. doi: 10.2215/CJN.01760213.
   PubMed Web of Science ®Google Scholar
• Sezai A, Soma M, Nakata K, et al. Comparison of febuxostat and allopurinol for hyperuricemia in cardiac surgery patients (NU-FLASH trial). Circ J. 2013;77(8):2043–2049. doi: 10.1253/circj.cj-13-0082.
   PubMed Web of Science ®Google Scholar
• Sircar D, Chatterjee S, Waikhom R, et al. Efficacy of febuxostat for slowing the GFR decline in patients with CKD and asymptomatic hyperuricemia: a 6-month, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis. 2015;66(6):945–950. doi: 10.1053/j.ajkd.2015.05.017.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Nakayama M, Kanno M, et al. Renoprotective effects of febuxostat in hyperuricemic patients with chronic kidney disease: a parallel-group, randomized, controlled trial. Clin Exp Nephrol. 2015;19(6):1044–1053. doi: 10.1007/s10157-015-1095-1.
   PubMed Web of Science ®Google Scholar
• Tani S, Nagao K, Hirayama A. Effect of febuxostat, a xanthine oxidase inhibitor, on cardiovascular risk in hyperuricemic patients with hypertension: a prospective, open-label, pilot study. Clin Drug Investig. 2015;35(12):823–831. doi: 10.1007/s40261-015-0349-8.
   PubMed Web of Science ®Google Scholar
• Beddhu S, Filipowicz R, Wang B, et al. A randomized controlled trial of the effects of febuxostat therapy on adipokines and markers of kidney fibrosis in asymptomatic hyperuricemic patients with diabetic nephropathy. Can J Kidney Health Dis. 2016;3:2054358116675343. doi: 10.1177/2054358116675343.
   Google Scholar
• Saag KG, Whelton A, Becker MA, et al. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis Rheumatol. 2016;68(8):2035–2043. doi: 10.1002/art.39654.
   PubMed Web of Science ®Google Scholar
• Gunawardhana L, Becker MA, Whelton A, et al. Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study. Arthritis Res Ther. 2018;20(1):99. doi: 10.1186/s13075-018-1593-0.
   PubMedGoogle Scholar
• Kimura K, Hosoya T, Uchida S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72(6):798–810. doi: 10.1053/j.ajkd.2018.06.028.
   PubMed Web of Science ®Google Scholar
• Mukri MNA, Kong WY, Mustafar R, et al. Role of febuxostat in retarding progression of diabetic kidney disease with asymptomatic hyperuricemia: a 6-months open-label, randomized controlled trial. Excli J. 2018;17:563–575.
   PubMed Web of Science ®Google Scholar
• Kojima S, Matsui K, Hiramitsu S, et al. Febuxostat for cerebral and cardiorenovascular events prevention study. Eur Heart J. 2019;40(22):1778–1786. doi: 10.1093/eurheartj/ehz119.
   PubMed Web of Science ®Google Scholar
• Wen H, Yongling Z, Shuying Z, et al. Effect of febuxostat on renal function in patients from South China with CKD3 diabetic nephropathy. J Bras Nefrol. 2020;42(4):393–399. doi: 10.1590/2175-8239-JBN-2019-0091.
   PubMedGoogle Scholar
• Yang N, Cao B. Low-dose febuxostat exhibits a superior renal-protective effect and non-inferior safety profile compared to allopurinol in chronic kidney disease patients complicated with hyperuricemia: a double-centre, randomized, controlled study. J Clin Pharm Ther. 2022;47(12):2214–2222. doi: 10.1111/jcpt.13794.
   PubMed Web of Science ®Google Scholar
• Kohagura K, Satoh A, Kochi M, et al. Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial. J Hypertens. 2023;41(9):1420–1428. doi: 10.1097/HJH.0000000000003484.
   PubMed Web of Science ®Google Scholar
• Nata N, Ninwisut N, Inkong P, et al. Effects of febuxostat on markers of endothelial dysfunction and renal progression in patients with chronic kidney disease. Sci Rep. 2023;13(1):13494. doi: 10.1038/s41598-023-40767-5.
   PubMed Web of Science ®Google Scholar
• Yang H, Li R, Li Q, et al. Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China. Int Urol Nephrol. 2023;55(5):1343–1352. doi: 10.1007/s11255-022-03437-5.
   PubMed Web of Science ®Google Scholar
• Chewcharat A, Chen Y, Thongprayoon C, et al. Febuxostat as a renoprotective agent for treatment of hyperuricaemia: a meta-analysis of randomised controlled trials. Intern Med J. 2021;51(5):752–762. doi: 10.1111/imj.14814.
   PubMed Web of Science ®Google Scholar
• Pisano A, Cernaro V, Gembillo G, et al. Xanthine oxidase inhibitors for improving renal function in chronic kidney disease patients: an updated systematic review and meta-analysis. Int J Mol Sci. 2017;18(11):2283. doi: 10.3390/ijms18112283.
   PubMed Web of Science ®Google Scholar
• Fujii K, Kubo A, Miyashita K, et al. Xanthine oxidase inhibitor ameliorates postischemic renal injury in mice by promoting resynthesis of adenine nucleotides. JCI Insight. 2019;4(22):e124816. doi: 10.1172/jci.insight.124816.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Yamamotoya T, Nakatsu Y, et al. Xanthine oxidase inhibitor febuxostat exerts an anti-inflammatory action and protects against diabetic nephropathy development in KK-Ay obese diabetic mice. Int J Mol Sci. 2019;20(19):4680. doi: 10.3390/ijms20194680.
   PubMed Web of Science ®Google Scholar
• Kim H, Baek CH, Chang JW, et al. Febuxostat, a novel inhibitor of xanthine oxidase, reduces ER stress through upregulation of SIRT1-AMPK-HO-1/thioredoxin expression. Clin Exp Nephrol. 2020;24(3):205–215. doi: 10.1007/s10157-019-01804-8.
   PubMed Web of Science ®Google Scholar
• Lu L, Zhu J, Zhang Y, et al. Febuxostat inhibits TGF‑β1‑induced epithelial‑mesenchymal transition via downregulation of USAG‑1 expression in Madin‑Darby canine kidney cells in vitro. Mol Med Rep. 2019;19(3):1694–1704.
   PubMed Web of Science ®Google Scholar
• Komers R, Xu B, Schneider J, et al. Effects of xanthine oxidase inhibition with febuxostat on the development of nephropathy in experimental type 2 diabetes. Br J Pharmacol. 2016;173(17):2573–2588. doi: 10.1111/bph.13527.
   PubMed Web of Science ®Google Scholar
• Alshahawey M, Shahin SM, Elsaid TW, et al. Effect of febuxostat on the endothelial dysfunction in hemodialysis patients: a randomized, placebo-controlled, double-blinded study. Am J Nephrol. 2017;45(5):452–459. doi: 10.1159/000471893.
   PubMed Web of Science ®Google Scholar
• Alshahawey M, Shaheen SM, Elsaid T, et al. Effect of febuxostat on oxidative stress in hemodialysis patients with endothelial dysfunction: a randomized, placebo-controlled, double-blinded study. Int Urol Nephrol. 2019;51(9):1649–1657. doi: 10.1007/s11255-019-02243-w.
   PubMed Web of Science ®Google Scholar
• FDA adds boxed warning for increased risk of death with febuxostat; [cited 2019 Feb 21]. Available from: https://www.fda.gov/media/120418/download.
   Google Scholar